Year: 2014
Type: article
Study design: Observational Study
Abstract: Background-Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann-Pick C1-like 1 (NPC1L1) protein.However, whether such inhibition reduces the risk of coronary heart disease is not known.Human mutations that inactivate a gene encoding a drug target can mimic the action of an inhibitory drug and thus can be used to infer potential effects of that drug.Methods-We sequenced the exons of NPC1L1 in 7364 patients with coronary heart disease and in 14,728 controls without such disease who were of European, African, or South Asian ancestry.We identified carriers of inactivating mutations (nonsense, splice-site, or frameshift mutations).In addition, we genotyped a specific inactivating mutation (p.Arg406X) in 22,590 patients with coronary heart disease and in 68,412 controls.We tested the association between the presence of an inactivating mutation and both plasma lipid levels and the risk of coronary heart disease.Results-With sequencing, we identified 15 distinct NPC1L1 inactivating mutations; approximately 1 in every 650 persons was a heterozygous carrier for 1 of these mutations.Heterozygous carriers of NPC1L1 inactivating mutations had a mean LDL cholesterol level that was 12 mg per deciliter (0.31 mmol per liter) lower than that in noncarriers (P = 0.04).Carrier status was associated with a relative reduction of 53% in the risk of coronary heart disease (odds ratio for carriers, 0.47; 95% confidence interval, 0.25 to 0.87; P = 0.008).In total, only 11 of 29,954 patients with coronary heart disease had an inactivating mutation (carrier frequency, 0.04%) in contrast to 71 of 83,140 controls (carrier frequency, 0.09%).Conclusions-Naturally occurring mutations that disrupt NPC1L1 function were found to be associated with reduced plasma LDL cholesterol levels and a reduced risk of coronary heart disease.(Funded by the National Institutes of Health and others.)Ezetimibe, a drug that is commonly prescribed to reduce plasma levels of low-density lipoprotein (LDL) cholesterol, inhibits the function of the protein encoded by the Niemann-Pick C1-like 1 gene (NPC1L1).1 NPC1L1 protein, which is expressed in the small intestine and liver, functions as a transporter of dietary cholesterol from the gut lumen into intestinal enterocytes.2,3 Because of its ability to block sterol absorption by about 50%, 4 ezetimibe lowers plasma LDL cholesterol levels by 15 to 20%. 5 However, it is uncertain whether
Source: New England Journal of Medicine
Author: The Myocardial Infarction Genetics Consortium Investigators
Institution: Washington University in St. Louis
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Brigham and Women's Hospital, Massachusetts General Hospital, Vanderbilt University, University of Wisconsin-Milwaukee, University of Pennsylvania, Ohio State University, University of Missouri, Cleveland Clinic, Foundation for Barnes-Jewish Hospital, University of Washington, Donovan Family Foundation, University of Ottawa, University of Dundee, Queen Mary University of London, University of Missouri-Kansas City, Wellcome Trust, Deutsches Zentrum für Herz-Kreislaufforschung, Università degli Studi di Milano, University of Texas Health Science Center at Houston, Broad Institute, National Institute for Health and Care Research, British Heart Foundation, University of Oxford, Fondation Leducq, Gentofte Hospital, King Abdulaziz University, Universität zu Lübeck, Rigshospitalet, Technische Universität München, National Institutes of Health, University of North Carolina at Chapel Hill, Perelman School of Medicine, University of Pennsylvania, Canadian Institutes of Health Research, Medical Research Council, Barts and The London School of Medicine and Dentistry, National Institute on Aging, National Heart, Lung, and Blood Institute, National Human Genome Research Institute, National Cancer Institute, National Institute of Nursing Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences, Stanford Cardiovascular Institute, School of Medicine, Stanford University
Awards: Comprehensive Sequencing and Analysis of Variation in NHLBI Cohorts, Rare coding variation and risk for myocardial infarction, NIHR Senior Investigator Award, CHARGE: Identifying Risk & Protective SNV for AD in ADSP Case-control Sample, Large Scale Sequencing and Analysis of Genomes, Statistical Methods in Chronic Disease Research, Northwest Genomics Center, UCLA Clinical and Translational Science Institute, G5413383169, Genomic variants associated with angina and health status outcome after MI, G7723204790, Vanderbilt Genome Electronic Records Project, Systematic approaches to the evaluation of emerging coronary risk markers. Large-scale epidemiological analyses of existing data and stored biological samples (renewal), Discovery of Mendelian Dyslipidemia and Heart Attack Genes Using Exome Sequencing, Diabetes Research Center (DRC), Integrated, Multidisciplinary Training in Cardiovascular Research, Large-scale integrative studies of risk factors in coronary heart disease: from discovery to application
OpenAlex ID: W2478496979
